We are live on ! Find out more
DMKJ

David M. Knott Jr Portfolio holdings

AUM $189M
1-Year Est. Return 67.72%
This Fund
S&P 500
This Quarter Est. Return
-2.49%
1 Year Est. Return
+67.72%
3 Year Est. Return
+169.37%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$168M
AUM Growth
-$47.9M
Cap. Flow
-$34.3M
Cap. Flow %
-20.4%
Top 10 Hldgs %
60.49%
Holding
95
New
8
Increased
17
Reduced
13
Closed
10

Top Buys

Rank Stock Value
1
IOVA icon
Iovance Biotherapeutics
IOVA
+$5.12M
2
AGIO icon
Agios Pharmaceuticals
AGIO
+$2.13M
3
RLMD icon
Relmada Therapeutics
RLMD
+$2.08M
4
ARDX icon
Ardelyx
ARDX
+$1.37M
5
TGTX icon
TG Therapeutics
TGTX
+$1.34M

Top Sells

Rank Stock Value
1
CLMT icon
Calumet Specialty Products
CLMT
+$44M
2
CPRX
Catalyst Pharmaceutical
CPRX
+$1.64M
3
TECX
Tectonic Therapeutic
TECX
+$1.54M
4
TVTX icon
Travere Therapeutics
TVTX
+$1.36M
5
BHVN icon
Biohaven
BHVN
+$1.25M

Sector Composition

Rank Sector Weight
1 Healthcare 53.57%
2 Financials 19.49%
3 Communication Services 15.66%
4 Technology 1.31%
5 Energy 0.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ATRC icon
26
AtriCure
ATRC
$2.21B
$1.47M 0.87%
51,400
– –
ARDX icon
27
Ardelyx
ARDX
$1.01B
$1.24M 0.74%
+207,000
New +$1.37M
CLOZ icon
28
Panagram BBB-B CLO ETF
CLOZ
$805M
$1.23M 0.73%
47,807
– –
JNJ icon
29
Johnson & Johnson
JNJ
$632B
$1.2M 0.72%
4,922
-2,000
-29% -$466K
RZLT icon
30
Rezolute
RZLT
$443M
$1.13M 0.67%
370,000
+30,000
+9% +$90K
OBIO icon
31
Orchestra BioMed
OBIO
$267M
$1.08M 0.64%
253,651
+3,651
+1% +$15.5K
MDGL icon
32
Madrigal Pharmaceuticals
MDGL
$11.7B
$1.05M 0.62%
2,000
– –
VERA icon
33
Vera Therapeutics
VERA
$2.08B
$1.05M 0.62%
26,000
– –
CNTB
34
Connect Biopharma Holdings
CNTB
$160M
$1.02M 0.6%
387,835
+187,835
+94% +$490K
IBB icon
35
iShares Biotechnology ETF
IBB
$9.77B
$929K 0.55%
5,500
– –
PFE icon
36
Pfizer
PFE
$153B
$908K 0.54%
32,337
– –
BMY icon
37
Bristol-Myers Squibb
BMY
$132B
$826K 0.49%
13,622
-8,378
-38% -$488K
CNQ icon
38
Canadian Natural Resources
CNQ
$98.1B
$819K 0.49%
16,800
– –
BIIB icon
39
Biogen
BIIB
$31.1B
$733K 0.44%
4,000
-2,000
-33% -$369K
RARE icon
40
Ultragenyx Pharmaceutical
RARE
$2.6B
$693K 0.41%
33,069
+13,063
+65% +$294K
AAPL icon
41
Apple
AAPL
$4.46T
$633K 0.38%
2,494
– –
MSFT icon
42
Microsoft
MSFT
$3.69T
$592K 0.35%
1,600
– –
VSTM icon
43
Verastem
VSTM
$604M
$551K 0.33%
+104,000
New +$641K
ADMA icon
44
ADMA Biologics
ADMA
$2.11B
$542K 0.32%
60,200
– –
IBM icon
45
IBM
IBM
$223B
$519K 0.31%
2,142
– –
PTHS
46
Pelthos Therapeutics
PTHS
$101M
$443K 0.26%
21,073
+1,792
+9% +$42.5K
KURA icon
47
Kura Oncology
KURA
$896M
$429K 0.26%
52,767
+13,558
+35% +$116K
EOLS icon
48
Evolus
EOLS
$530M
$408K 0.24%
99,338
– –
CGEM icon
49
Cullinan Oncology
CGEM
$1.26B
$344K 0.2%
+24,200
New +$311K
SLDB icon
50
Solid Biosciences
SLDB
$974M
$339K 0.2%
47,143
-115,297
-71% -$741K
1
2
3 4

Similar funds

SF
Steffes Financial Overland Park, Kansas $189M AUM
WDOM
Wasserstein Debt Opportunities Management New York $189M AUM 169.75% 1-Year Est. Return
BC
Beaconlight Capital New York $190M AUM 95.82% 1-Year Est. Return
CFA
Camarda Financial Advisors Fleming Island, Florida $190M AUM 48.71% 1-Year Est. Return
HCM
Harspring Capital Management New York $190M AUM 19.3% 1-Year Est. Return
RCAP
Resolute Capital Asset Partners Denver, Colorado $190M AUM 160.65% 1-Year Est. Return
AAA
American Alpha Advisors New York $188M AUM 42.65% 1-Year Est. Return
CCM
Clearfield Capital Management New York $188M AUM 84.86% 1-Year Est. Return

David M. Knott Jr's Q1 2026 Portfolio in Review

As of Q1 2026, David M. Knott Jr held 95 positions worth $168M, down 22% from $216M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

David M. Knott Jr withdrew a net $34.3M in Q1 2026, closing 10 positions and reducing 13 holdings. Its most notable exit was Calumet Specialty Products, an estimated $44M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 54% of assets, up from 41% a quarter earlier, followed by Financials and Communication Services.

Against the trend, David M. Knott Jr opened a new position in Iovance Biotherapeutics worth $5.62M.

  • David M. Knott Jr's largest Q1 2026 buy was Iovance Biotherapeutics: 1,600,000 shares worth $5.62M.
  • David M. Knott Jr added most to Agios Pharmaceuticals in Q1 2026, an estimated $2.13M increase.
  • David M. Knott Jr's biggest Q1 2026 reduction was Catalyst Pharmaceutical, cutting an estimated $1.64M.
  • David M. Knott Jr fully exited Calumet Specialty Products in Q1 2026, selling an estimated $44M.
  • David M. Knott Jr's ten largest holdings make up 60% of its $168M portfolio in Q1 2026.
  • David M. Knott Jr opened 8 new positions and closed 10 in Q1 2026.
  • David M. Knott Jr's portfolio value fell 22% quarter-over-quarter to $168M.

Based on David M. Knott Jr's 13F filing for Q1 2026, filed 14 May 2026.